Since dysregulated lipid metabolism has been regarded as the critical factor in cardiovascular events, the recovery of lipid profiles in psoriasis patients indicates that IL-17A mAbs might have a protective effect against CVDs. This evidence concerns the gene IL17A and psoriasis.